Higher doses of the kinase inhibitor brigatinib as second-line therapy for ALK-positive non–small-cell lung cancer may be an option for some patients.
Researchers at Weill Cornell Medicine are reporting that they have successfully converted cells from blood vessels in mice into blood-forming stem cells.
A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.
Researchers have now mapped genetic changes that help drive glioblastoma and are hoping this will lay the foundation for targeted treatment of the disease.
Researchers at Seattle Children's Research Institute announced the first-in-human clinical trial aimed to extend remission for children and young adults with leukemia treated with CAR T-cell immunotherapy.
Researchers from Johns Hopkins University report on a cascade of events that appears to correlate with early cancer recurrence and decreased overall survival.
A new study is suggesting that intravenous and subcutaneous rituximab share similar efficacy and safety profiles.
A new study is suggesting there may be an association with high tumor levels of the protein PD-L1 and head and neck disease recurrence.
New evidence is suggesting that extensive immune profiling of sarcomas may unlock likely subtypes susceptible to immunotherapy.
Researchers report that an analysis of ALK copy number in circulating tumor cells before starting crizotinib treatment and after 2 months of crizotinib treatment may provide a biomarker for predicting the effectiveness of the drug.